BioLumic is a U.S.- and New Zealand-based agricultural biotechnology company using light signaling as a programming language for plants.
 

Cyclarity Therapeutic’s modeling platform designs synthetic molecules targeting a variety of age-related diseases. Its first candidate is currently in human trials to treat and repair the world’s biggest killer, atherosclerotic cardiovascular disease.
 

Kanvas Biosciences is a microbiome therapeutics company developing a novel multi-omics spatial biology and manufacturing platform to unlock the microbiome as a druggable organ system.
 

Nimble have developed an efficient way to sample the upper gastrointestinal tract to step-change microbiome and food-digestion analytics.
 

Prolific Machines is redefining biologics manufacturing with its pioneering Photomolecular platform, leveraging proprietary optogenetics tools and closed-loop control capabilities to address major protein production challenges.
 

Floré by Sun Genomics is a tech-driven microbiome innovator leveraging proprietary data to create clinically tested, science-backed personalized synbiotics.
 

A venture capital fund targeting innovations in human and planetary health sectors. 
 

DNA sequencing company developing a new innovative approach that leverages plasmonic nanoantenna to provide scalable DNA sequencing without compromise to read length, cost or accuracy.
 

Tune Therapeutics is pioneering epigenetic medicine through its innovative TEMPO platform, which controls gene expression without cutting or altering DNA sequences. This unique “genetic tuning” technology expands the frontiers of genetic medicine beyond rare disorders, to address common and chronic diseases affecting millions worldwide.